JP2016510315A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510315A5
JP2016510315A5 JP2015548630A JP2015548630A JP2016510315A5 JP 2016510315 A5 JP2016510315 A5 JP 2016510315A5 JP 2015548630 A JP2015548630 A JP 2015548630A JP 2015548630 A JP2015548630 A JP 2015548630A JP 2016510315 A5 JP2016510315 A5 JP 2016510315A5
Authority
JP
Japan
Prior art keywords
combination
combination according
tissue factor
fusion protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015548630A
Other languages
English (en)
Japanese (ja)
Other versions
JP6518591B2 (ja
JP2016510315A (ja
Filing date
Publication date
Priority claimed from EP12198839.8A external-priority patent/EP2745852A1/en
Application filed filed Critical
Publication of JP2016510315A publication Critical patent/JP2016510315A/ja
Publication of JP2016510315A5 publication Critical patent/JP2016510315A5/ja
Application granted granted Critical
Publication of JP6518591B2 publication Critical patent/JP6518591B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015548630A 2012-12-21 2013-12-20 シーラント組成物 Expired - Fee Related JP6518591B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12198839.8 2012-12-21
EP12198839.8A EP2745852A1 (en) 2012-12-21 2012-12-21 Sealant compositions
PCT/EP2013/077674 WO2014096354A1 (en) 2012-12-21 2013-12-20 Sealant compositions

Publications (3)

Publication Number Publication Date
JP2016510315A JP2016510315A (ja) 2016-04-07
JP2016510315A5 true JP2016510315A5 (enExample) 2017-02-09
JP6518591B2 JP6518591B2 (ja) 2019-05-22

Family

ID=47563088

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015548630A Expired - Fee Related JP6518591B2 (ja) 2012-12-21 2013-12-20 シーラント組成物

Country Status (17)

Country Link
US (1) US20160082145A1 (enExample)
EP (2) EP2745852A1 (enExample)
JP (1) JP6518591B2 (enExample)
CN (1) CN104955493A (enExample)
AU (1) AU2013366544B2 (enExample)
BR (1) BR112015014926B1 (enExample)
CY (1) CY1118938T1 (enExample)
DK (1) DK2934612T3 (enExample)
ES (1) ES2627053T3 (enExample)
HR (1) HRP20170880T1 (enExample)
HU (1) HUE034649T2 (enExample)
LT (1) LT2934612T (enExample)
MX (1) MX361222B (enExample)
PL (1) PL2934612T3 (enExample)
PT (1) PT2934612T (enExample)
SI (1) SI2934612T1 (enExample)
WO (1) WO2014096354A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109010906B (zh) * 2018-08-16 2021-05-14 陈明远 一种促进术后伤口局部止血及促进术后创面上皮化的生物胶水及其工作方法
US11666682B2 (en) * 2020-08-31 2023-06-06 Ethicon, Inc. Method of stopping CSF leaks and apparatus therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69530914T2 (de) * 1994-02-17 2004-03-11 New York Blood Center, Inc. Biologische bioadhäsive präparate, die fibrinkleber und liposomen enthalten, verfahren für ihre herstellung und verwendung
WO1997029792A1 (en) * 1996-02-20 1997-08-21 Cohesion Corporation Tissue sealant compositions and methods of use thereof
WO1999018931A1 (en) * 1997-10-10 1999-04-22 University Of Virginia Use of fibrin sealant to maintain hemostasis, lymphostasis and prevent local accumulation of body fluids
EP1749536A1 (en) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Activated factor X stimulants as new antihemorrhagic agents for topical use
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
EP2145695A1 (de) 2008-07-14 2010-01-20 Sika Technology AG Vorrichtung zur Klebstoffapplikation
EP2380905A1 (en) 2010-04-19 2011-10-26 Thrombotargets Europe, S.L. Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof

Similar Documents

Publication Publication Date Title
WO2017100700A3 (en) Peptides for renal therapy
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
CA2796215C (en) Compositions and methods for brain delivery of analgesic peptides
WO2010048275A3 (en) Lyophilized recombinant vwf formulations
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
HK1207097A1 (en) Fusion proteins for treating a metabolic syndrome
WO2014150600A3 (en) Modified toxins
NZ603200A (en) Peptides and their use
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
MX391804B (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
NZ702801A (en) Treatment of sanfilippo syndrome type b
WO2014150375A3 (en) Treatment of collagen defects using protein solutions
HK1216617A1 (zh) 用人生长激素类似物治疗小儿生长激素缺乏症
EP2924049A4 (en) TROPHIC HORMONFUSION PROTEIN, METHOD OF MANUFACTURE AND APPLICATION THEREOF
PH12013500108A1 (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
CL2007003754A1 (es) Compuestos derivados de aril(heteroaril)alquil-amina; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como bronquitis, enfisema pulmonar y epoc.
EA201691008A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-a]пиридо[3,4-e]пиримидин-5(1h)-он, его соли и способы применения
JP2010538020A5 (enExample)
WO2010132690A3 (en) Compositions and methods for promoting tissue repair and wound healing
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
WO2014204854A8 (en) Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
JP2016510315A5 (enExample)